TYRA - CIK 0001863127
The table below shows Tyra Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $102.93M | $80.08M | $62.52M | $43.01M | $20.64M | $7.20M |
| SG&A | $29.83M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $24.10M |
| $17.43M |
| $15.92M |
| $5.65M |
| $2.09M |
| Operating income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M | -$9.30M |
| Income tax | $0.00 | $0.00 | $0.00 | $2.00K | $1.00K | $1.00K |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M | -$9.34M |
| EPS (diluted) | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | - |